Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 23, 2024
Daily News
August 23, 2024
- A Time for Patience - 2: Will High-Dose Mecobalamin and Tofersen Become First-Line Treatments in ALS?
August 23, 2024
- Xolair SC Pen Versions Go on Sale in Japan: Novartis
August 23, 2024
- Leqembi Approved in UK: Eisai
August 23, 2024
- Astellas Pharma Employee Indicted in China
August 23, 2024
- New LDP Study Group Seeks Budget to Bolster Immunoglobulin Production
August 23, 2024
- Bayer Japan Says No Job Cuts to Soothe Employees’ Nerves as Xarelto Generics Loom
August 23, 2024
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…